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C1q/TNF-related protein 3 (CTRP3) and 9
(CTRP9) concentrations are decreased in
patients with heart failure and are
associated with increased morbidity and
mortality
Chao Gao1†, Shasha Zhao1†, Kun Lian1, Baibing Mi2, Rui Si1, Zhijun Tan3, Feng Fu4, Shuai Wang1, Rutao Wang1,
Xinliang Ma5 and Ling Tao1*

Abstract
Background: Biochemical marker has revolutionized the approach to the diagnosis of heart failure. However, it
remains difficult to assess stability of the patient. As such, novel means of stratifying disease severity are needed.
C1q/TNF-Related Protein 3 (CTRP3) and C1q/TNF-Related Protein 9 (CTRP9) are novel adipokines that contribute to
energy homeostasis with additional anti-inflammatory and anti-ischemic properties. The aim of our study is to
evaluate concentrations of CTRP3 and CTRP9 in patients with HFrEF (heart failure with reduced ejection fraction)
and whether associated with mortality.
Methods: Clinical data and plasma were obtained from 176 healthy controls and 168 patients with HFrEF. CTRP3
and CTRP9 levels were evaluated by enzyme-linked immunosorbent assay.
Results: Both CTRP3 and CTRP9 concentrations were significantly decreased in the HFrEF group compared to the
control group (p < 0.001). Moreover, patients with higher New York Heart Association class had significantly lower
CTRP3 or CTRP9 concentrations. Correlation analysis revealed that CTRP3 and CTRP9 levels were positively related
with LVEF% (CTRP3, r = 0.556, p < 0.001; CTRP9, r = 0.526, p < 0.001) and negatively related with NT-proBNP levels
(CTRP3, r = − 0.454, p < 0.001; CTRP9, r = − 0.483, p < 0.001). After a follow up for 36 months, after adjusted for age,
LVEF and NT-proBNP, we observed that CTRP3 or CTRP9 levels below the 25th percentile was a predictor of total
mortality (CTRP3,HR:1.93,95%CI1.03~3.62,P = 0.042;CTRP9,HR:1.98,95%CI:1.02~3.85,P = 0.044) and hospitalizations
(CTRP3,HR:2.34,95% CI:1.43~3.82,P = 0.001;CTRP9,HR:2.67,95%CI:1.58~4.50,P < 0.001).
Conclusions: CTRP3 and CTRP9 are decreased in patients with HFrEF, proportionate to disease severity, and each is
associated with increased morbidity and mortality.
Trial registration: NCT01372800. Registered May 2011.
Keywords: Biomarker, C1q/TNF-related Protein3 (CTRP3), C1q/TNF-related Protein9 (CTRP9), Heart failure with
reduced ejection fraction
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Background
The discovery of novel risk markers for heart failure (HF)
has contributed to improved screening, prevention, diagnosis and treatment of HF [1, 2]. Up to now, BNP and NTproBNP are the most widely used biomarkers in clinical
practice, such testing is recommended in current guidelines in determining the diagnosis and prognosis of HF.
However, in certain cases, such as for extremely high BNP
or NT-proBNP levels, these biomarkers cannot reflect the
severity of HF or morphologic changes of the heart. Besides, increased NT-proBNP levels may reflect diminished
renal function, left ventricular wall stress, or both. As such,
novel means of stratifying disease severity are still needed.
Fat tissue contributes to energy homeostasis and can secrete a number of adipokines that have cardioprotective
properties [3]. During heart failure, the secretion of adipokines is dysregulated [4]. However, the dysfunction of adipokines secretion in fat tissue cannot currently be easily
measured. Researches have shown adiponectin level was a
predictor of mortality, independent of risk markers of CHF
severity. However, the levels of adiponectin in healthy
people can range from 5 to 30 μg/ml [5]. It is hard to set
the cutoff point between healthy and HF subjects. Interestingly, adiponectin have been recently found belonging to
CTRP family [6]. The number of proteins in the CTRP
family currently comprises 15 members in addition to adiponectin. Among them, in our previous in vivo studies, we
found CTRP (C1q/TNF-Related Protein) 3 and CTRP9
were closely related to cardiovascular diseases [7–9].
CTRP3 is mainly expressed in mammalian subcutaneous
and visceral adipocytes [10]. CTRP3 can lower blood glucose in both normal and ob/ob mice without affecting insulin or adiponectin levels [11]. CTRP3 is also found to be an
anti-inflammatory adipokine [12] that inhibits proinflammatory pathways such as fatty acid-, LPS- and Toll-like receptor (TLR)-mediated inflammation in monocytes and
adipocytes [13]. Moreover, CTRP3 promotes vascular
smooth muscle cell proliferation in blood vessel wall after
vascular injury [14]. CTRP9 is predominantly expressed in
primary adipocytes and stromal cells [15]. CTRP9 can also
reduce blood glucose and insulin levels without effecting
body weight or food intake. CTRP9 is also a vasorelaxative
adipocytokine that may exert vasculoprotective effects via
the adiponectin receptor 1/AMPK/eNOS dependent/NO
mediated signaling pathway [16]. In an in vivo MI model,
we and others found CTRP3 [7] or CTRP9 [17] can improve
survival rate, restored cardiac function, attenuated cardiomyocyte apoptosis, attenuated adverse remodeling, increased re-vascularization. However, to date, the levels of
CTRP3 and CTRP9 have not been reported in patients with
heart failure, and consequently, their possible role in relation
to the severity and mortality of heart failure is unknown.
To analysis the correlation of CTRP3, CTRP9 and
HFrEF, we measured levels of CTRP3 and CTRP9 in
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clinically controlled HFrEF patients of various degrees of
severity. Further, in a 3-year follow up, we studied their association with morbidity and mortality.

Methods
Study population

Patients with heart failure with reduced EF that were admitted to the Department of Cardiology at Xijing Hospital,
Xian, China, between May 2012 and September 2012, were
consecutively recruited for this study. One hundred sixtyeight chronic heart failure patients (122 men and 46
women) were recruited. The diagnosis of HFrEF was made
on the basis of clinical history, a chest roentgenogram, an
electrocardiogram and an echocardiogram. The inclusion
criterion was a diagnosis of heart failure (left ventricular
EF < 40%). Severity of disease was assessed according to
the New York Heart Association (NYHA) standards and
fell within functional classes II to IV. Exclusion criteria for
the study were hypotension [SBP ≤ 90 mmHg (1 mmHg =
0.133 kPa)], cardiogenic shock, severe bradycardia (resting
heart rate ≤ 60 beats /min), atrioventricular block (more
than II degree), ongoing acute exacerbation of heart failure,
malignancy, acute systemic infections, acute or chronic
liver disease or renal failure. The control group paired by
age and sex consisted of 176 healthy subjects (116 men
and 60 women) who underwent physical examinations,
blood analysis and echocardiographic evaluations as a part
of a routine health check-up in the health promotion center of Xijing Hospital between May 2012 and June 2012.
Follow up

The study main end-points were all-cause death and the
second outcomes was re-hospitalization rates. Patients
were followed up by telephone once every 3 months for a
minimum of 36 months. During the whole follow up
period, eight patients were lost to follow up. The baseline
characteristics of the patients who were lost to follow-up
were not significantly different from the others, thus they
were not included in the survival analyses.
Laboratory measurements

After a minimum 8-h overnight fast, venous blood was
drawn into EDTA tubes and promptly centrifuged at 4 °C,
and plasma was frozen at − 70 °C for subsequent assays.
Plasma glucose, total cholesterol, low-density lipoprotein
and high-density lipoprotein cholesterol, triglycerides,
serum creatinine, urea nitrogen, uric acid and cystatin c
levels were analyzed by applying the standard protocols of
the hospital biochemistry laboratory. NT-proBNP was
measured by a double-antibody sandwich technique with
electrochemiluminescence as signal (Elecsys 2010, Roche
Diagnostics). ELISA was used for measurement of CTRP3
and CTRP9 (Shanghai LianShuo Biological Technology
Co, China; The intra-assay and interassay coefficients of
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variation were below 5%). No significant cross-reactivity or
interference between human CTRP3 and CTRP9 was observed in our pilot experiment.
Statistical analysis

Statistical analysis was performed with the Statistical Package for Social Sciences for Windows (IBM, SPSS version
19.0) and graphs were made by Prism 6 (GraphPad software). To observe the possible difference in CTRP3/
CTRP9 levels between healthy control and HFrEF patients,
sample size was calculated by PASS 11 (NCSS). Sample
sizes of 164 subjects in control group and 164 subjects in
HFrEF group achieve 90% power to detect a difference of
− 30.0 between the null hypothesis that both group means
are 0.0 and the alternative hypothesis that the mean of
HFrEF group is 30.0 with estimated group standard deviations of − 70.0 and 70.0 and with a significance level
(alpha) of 0.01 using a two-sided two-sample t-test. All variables were tested for normality and log transformed was
performed for the variables which were not non-normality.
Continuous variables are expressed as mean ± standard
deviation (mean ± SD) unless otherwise stated. Categorical variables were analyzed as value and percentage.
Continuous data with a normal distribution were compared with the Student t or ANOVA tests. Chi-square
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test was used to test for differences in the distribution of
categorical variables. Correlations between CTRP3 or
CTRP9 levels and other variables were evaluated by
Pearson correlation coefficient analysis. Event rates were
compared by Kaplan-Meier curves calculated for CTRP3
or CTPR9 above or below the 25th percentile. The independent predictive power of CTRP3 or CTRP9 and
other clinical and demographic variables for death and
hospitalizations for HFrEF was tested by stepwise Cox
proportional hazards regression analyses. The analyses
are presented as HR with a 95% confidence interval (CI).
P values < 0.05 were considered significant.

Results
Baseline characteristics

The clinical and biochemical characteristics of the study
subjects are presented in Table 1. At total of 168 HFrEF
patients were recruited. 65% of the patients were treated
with an ACE inhibitor, 36% were treated with an angiotensin II antagonist, 69% received a β-blocker, 80% were
treated with digoxin and 80% were using a diuretic. The
HFrEF group showed significantly increased BMI, LDLC, triglycerides, serum creatinine and cystatin c and NTproBNP compared to the control group. LVEF%, HDL-C
and total cholesterol levels in the HFrEF group were

Table 1 Clinical and biochemical characteristics of control and HFrEF groups
Variables

Control (n = 176)

HFrEF (n = 168)

P

Age (years)

55.11 ± 13.44

57.25 ± 14.92

0.418

Sex, male (%)

116 (65.9%)

122(72.6%)

0.199

BMI (Kg/m )

21.72 ± 1.78

23.45 ± 3.80

< 0.001

Diabetes mellitus (%)

0(0%)a

40 (23.8%)

< 0.001

Hypertension (%)

a

0(0%)

66 (39.3%)

< 0.001

Myocardial infarction (%)

0(0%)a

52 (31.0%)

< 0.001

Systolic pressure (mmHg)

108.86 ± 15.70

119.04 ± 20.71

0.071

Diastolic pressure (mmHg)

71.41 ± 10.90

75.96 ± 12.80

0.577

Fasting glucose (mmol/L)

4.72 ± 0.35

5.00 ± 1.75

0.004

HDL-cholesterol (mmol/L)

1.31 ± 0.19

0.93 ± 0.28

< 0.001

LDL-cholesterol (mmol/L)

1.67 ± 0.34

2.33 ± 0.88

< 0.001

Total Cholesterol (mmol/L)

4.16 ± 0.51

3.71 ± 0.98

0.001

2

Triglyceride (mmol/L)

0.95 ± 0.24

1.39 ± 0.86

< 0.001

Serum creatinine (umol/L)

91.11 ± 6.58

113.79 ± 32.89

< 0.001

Cystatin c (mg/L)

1.05 ± 0.23

1.38 ± 0.42

< 0.001

NT-proBNP (ng/L)

3.81 ± 2.55

9878.69 ± 9236.14

< 0.001

LVEF (%)

59.25 ± 2.35

28.67 ± 6.18

< 0.001

CTRP3 (ng/mL)

236.40 ± 62.86

173.30 ± 49.81

< 0.001

CTRP9 (ng/mL)

180.70 ± 51.05

124.60 ± 37.58

< 0.001

Data are expressed as mean ± SD or frequency (%)
P-values were calculated by an independent-samples t-test or chi-square test
BMI Body mass index, HDL High-density lipoprotein, LDL Low-density lipoprotein, NT-proBNP N-terminal pro-brain natriuretic peptide, LVEF Left ventricular ejection
fraction, CTRP3 C1q/TNF-related protein 3, CTRP9 C1q/TNF-related protein 9
a
These data were acquired by inquiry of medical history
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significantly lower than in the control group. Meanwhile,
age, sex, diastolic and systolic blood pressure in these
two groups showed no significant differences.
CTRP3 and CTRP9 levels and correlation with clinical
parameters

Compared with control subjects, the concentrations of
CTRP3 and CTRP9 were significantly decreased in patients
with HFrEF (Table 1, P < 0.001, respectively). Multivariable
linear regression analyses was then preformed. Results analyzed in all enrolled subjects demonstrated that Age, hypertension, NT-ProBNP, LEVF% were found to be associated
with CTRP3 and CTRP9. We than set HFrEF as the outcome variable and CTRP 3/9 and other variables as predictor in a logistic model. Results were shown in Table 2.
While HFrEF as the outcome variable, Age, Total Cholesterol, CTRP3 or CTRP9 exhibited statistical significance.
Subsequently, we analyzed relationships between
CTRP3/CTRP9 and NYHA class, LVEF% and NT-proBNP
in HFrEF patients. 24.4% (41 patients) of the patients with
HFrEF were NYHA functional class II, 47.0% (79) were
NYHA III and 28.6% (48) were NYHA IV. We found the
more advanced the HFrEF symptom status according to
NYHA class, the lower the CTRP3 and CTRP9 concentrations were (Fig. 1a and b). Pearson correlation analysis also
revealed that in the HFrEF group, both CTRP3 and CTRP9
concentrations were positively correlated with LVEF%
(CTRP3, r = 0.556, P < 0.001; CTRP9, r = 0.526, P < 0.001)
and inversely associated with the log index of NT-proBNP
levels (CTRP3, r = − 0.454, P < 0.001; CTRP9, r = − 0.483,
P < 0.001) (Fig. 1c to f).
Most human adipose cytokines levels are affected by
estrogen. To our surprise, we found that plasma CTRP3
and CTRP9 concentrations were not different according
to sex in either the control group or the HFrEF group
(Fig. 2a and b). To our surprise, we also observed that
CTRP3 and CTRP9 concentrations manifested a significantly positive relationship in both healthy subjects and
HFrEF patients (control subjects, r = 0.916, P < 0.001;
HFrEF subjects, r = 0.800, P < 0.001) (Fig. 2c and d).

Survival analyses

To investigate if lower CTRP3/CTRP9 is related with
higher death rates or re-hospitalization rates in HFrEF
patients, we tried to dichotomize CTRP3/CTRP9 levels for
further analysis. Because CTRP3 and CTRP9 are novel
adipokines and they have never been reported data
showing their concentrations in heart failure patients, we
dichotomize CTRP3 and CTRP9 by 25th percentile, 50th
percentile and 75th percentile and tested to observe
whether there are statistical significance in survive analysis.
Results showed that while dichotomize CTRP3 and CTRP9
by 25th percentile, Kaplan-Meier analysis revealed differences in 3 years of follow-up in death and free-ofhospitalization above and below the first quartile of plasma
CTRP3 or CTRP9. Supported by these findings, the
CTRP3 and CTRP9 were dichotomize by 25th percentile
for further analysis. Clinical and laboratory variables
according to 25th percentile of baseline CTRP3 or CTRP9
levels in HFrEF patients are presented in Table 3. We
found that patients in the lower quartile of CTRP3 levels
manifested lower morbidity related to hypertension, lower
rates of LVEF> 25% and lower NT-proBNP< 20,000 ng/L
and surprisingly younger age. Similarly, patients in the
lower CTRP9 quartile were associated with a lower
morbidity of hypertension, total cholesterol and lower rate
LVEF> 25% and NT-proBNP< 20,000 ng/L.
During the 3 years of follow-up, 58 (36.3%) of the patients died in the HFrEF group, whereas 93 (58.1%) were
hospitalized for HFrEF deterioration. Kaplan-Meier analysis revealed differences in event-free events for death
and free-of-hospitalization when the group was divided
according to concentrations above and below the first
quartile of plasma CTRP3 (136.87 ng/ml) or CTRP9
(100.75 ng/ml) (Fig. 3). The unadjusted overall mortality
risk was markedly elevated in the patients in the first
quartile of CTRP3 (P = 0.009). This observation was in
accordance with the markedly increased HFrEF
hospitalization rates in these subjects (P = 0.001). Similarly, the unadjusted overall mortality risk and HFrEF
hospitalization free rates were also markedly elevated in

Table 2 Logistics regression analyses
P

OR

P

95% CI. for OR
Lower

Upper

OR

95% CI. for OR
Lower

Upper

Age (years)

0.000

1.121

1.064

1.182

Age (years)

0.000

1.134

1.068

1.205

Sex(%)

0.246

1.965

0.628

6.146

Sex(%)

0.109

2.852

0.790

10.287

2

2

BMI (kg/m )

0.509

1.061

0.890

1.265

BMI (kg/m )

0.328

1.102

0.907

1.340

Serum Creatinine (μmol/L)

0.045

1.044

1.001

1.088

Serum Creatinine (μmol/L)

0.074

1.046

0.996

1.099

Cystatin C (mg/L)

0.387

0.504

0.107

2.379

Cystatin C (mg/L)

0.642

0.680

0.134

3.458

Total cholesterol (mmol/L)

0.000

0.251

0.117

0.540

Total cholesterol (mmol/L)

0.001

0.244

0.103

0.581

Triglyceride (mmol/L)

0.002

23.336

3.264

166.867

Triglyceride (mmol/L)

0.001

48.693

4.998

474.405

CTRP3 (ng/mL)

0.000

0.977

0.967

0.987

CTRP9 (ng/mL)

0.000

0.960

0.945

0.977
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Fig. 1 Concentration of CTRP3 (a) and CTRP9 (b) according to the severity of HFrEF stratified by NYHA functional class. Scatterplots of the
association between CTRP3/CTRP9 and LVEF% (c and d) and with log transformed values of NT-proBNP (e and f) in HFrEF patients. *p < 0.05,
**p < 0.01 vs. Control group

the subjects in the first quartile of CTRP9 (P < 0.001,
respectively).
Multivariate analysis by stepwise Cox proportional
hazards regression analysis confirmed that plasma CTRP3
concentrations (determined dichotomously, adjusted for age,
hypertension,
LVEF> 25%,
NT-proBNP< 20,000 ng/L)
remained independently predictive of death with a hazard
risk ratio of 1.93 (95% CI 1.03 to 3.62, P = 0.042). Moreover,
CTPR3 concentration was also an independent predictor of
HFrEF hospitalization free rates during the follow up period
with a hazard risk ratio of 2.34 (95% CI 1.43 to 3.82 P =
0.001). Similarly, CTRP9 (determined dichotomously, adjusted for hypertension, diabetes, LVEF> 25%, NT-proBNP<
20,000 ng/L, diastolic pressure and total cholesterol) was
also found to be independently predictive of death with a

hazard risk ratio of 1.98 (95% CI 1.02 to 3.85, P = 0.044) and
a predictor of free of HFrEF hospitalization with a hazard
risk ratio of 2.67 (95% CI 1.58 to 4.50, P < 0.001).

Discussion
Heart failure is emerging rapidly as a major cause of morbidity and mortality around the world. As such, novel
means of stratifying disease severity are needed. Here, in a
prospective cohort of patients with HFrEF, we report that
CTRP3 and CTRP9 levels are decreased in patients with
HFrEF in a manner proportionate to symptom severity
(NYHA class). Consistent with that, levels of these 2 adipokines were inversely associated with markers of HFrEF
severity, such as LVEF and NT-proBNP. We also observed
a significant relationship between CTRP3 and CTRP9
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Fig. 2 Distribution of CTRP3 and CTRP9 according to sex (a and b). Correlation between CTRP3 and CTRP9 in control group (c) and HFrEF
group (d)

Table 3 Baseline characteristics according to 25 percentile of CTRP3 and CTRP9 levels
Variables

CTRP3 (ng/ml)
≤136.87 (n = 42)

CTRP9 (ng/ml)
> 136.87 (n = 126)

P

≤100.75 (n = 42)

> 100.75 (n = 126)

P

Age (years)

51.74 ± 19.16

59.09 ± 12.80

0.019

51.48 ± 17.58

59.17 ± 13.47

0.142

Sex,male (%)

32(76.2%)

90(71.4%)

0.549

31(73.8%)

91(72.2%)

0.842

BMI (kg/m )

22.80 ± 3.86

23.66 ± 3.77

0.933

22.30 ± 3.59

23.83 ± 3.80

0.462

Diabetes mellitus (%)

7(16.7%)

33(26.2%)

0.209

6(14.3%)

34(27.0%)

0.094

2

Hypertension (%)

10(23.8%)

56(44.4%)

0.018

7(16.7%)

59(46.8%)

0.001

Myocardial infarction (%)

12(28.6%)

40(31.7)

0.700

9(21.4%)

43(34.1%)

0.123

Disease duration (months)

44.40 ± 56.92

33.21 ± 36.44

0.237

38.81 ± 42.59

35.07 ± 42.70

0.574

Systolic pressure (mmHg)

113.05 ± 22.334

121.03 ± 19.83

0.287

111.71 ± 20.92

121.48 ± 20.14

0.822

Diastolic pressure (mmHg)

73.45 ± 14.61

76.80 ± 12.09

0.443

71.43 ± 9.98

77.48 ± 13.30

0.021

Fasting glucose (mmol/L)

4.75 ± 1.43

5.08 ± 1.83

0.275

4.45 ± 1.10

5.18 ± 1.88

0.059

HDL-cholesterol (mmol/L)

0.86 ± 0.26

0.96 ± 0.29

0.865

0.87 ± 0.30

0.95 ± 0.28

0.486

LDL-cholesterol (mmol/L)

2.11 ± 0.84

2.40 ± 0.88

0.839

2.12 ± 0.83

2.40 ± 0.89

0.731

Total Cholesterol (mmol/L)

3.45 ± 1.00

3.80 ± 0.96

0.842

3.45 ± 0.98

3.80 ± 0.97

0.015

Triglyceride (mmol/L)

1.27 ± 0.71

1.42 ± 0.90

0.332

1.15 ± 0.56

1.47 ± 0.92

0.873

Serum creatinine (umol/L)

123.69 ± 36.954

110.49 ± 30.89

0.214

119.33 ± 34.45

111.94 ± 32.30

0.547

Cystatin c (mg/L)

1.48 ± 0.43

1.35 ± 0.42

0.428

1.40 ± 0.39

1.37 ± 0.44

0.828

NT-proBNP<20,000 (ng/L)

25 (59.5%)

121(96%)

< 0.001

27(64.3%)

119(94.4%)

< 0.001

LVEF> 25%

19 (45.2%)

103(81.7%)

< 0.001

21 (50%)

101 (80.2%)

< 0.001
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Fig. 3 Kaplan-Meier survival curves according to the above or below 25th centile of CTRP3 or CTRP9 concentrations. a Event free survival rate of
CTRP3. b Free of HFrEF hospitalization rates of CTRP3. c Event free survival rate of CTRP9. d Free of HFrEF hospitalization rates of CTRP9

levels. Finally, decreased levels of CTRP3 and CTRP9
were each associated with increased mortality and
hospitalization.
CTRP is a widely expressed and highly conserved adipokine family of adiponectin paralogs [18]. The number of
proteins in the CTRP family is rapidly growing and currently comprises 15 members in addition to adiponectin
[6]. CTRPs principally form highly stable, biologically active
homotrimers and control adipocyte physiology as well as
energy homeostasis [18]. In previous preclinical research,
using an in vivo mouse myocardial ischemia model, we
found that supplementing CTRP3 [7] or CTRP9 [9] can
attenuate post-MI remodeling and augment post-MI
contractile function through their anti-apoptotic and
pro-angiogenic properties. However, little is known about
the levels of CTRP3 and CTRP9 in patients with disease. In
previous studies, data suggested that patients with acute
coronary syndrome or stable angina pectoris had significantly lower plasma CTRP3 concentrations compared with
control subjects [8]. In addition, previous data also showed
decreased CTRP3 in obese populations [19] . No data have
existed regarding CTRP9 in patients with cardiovascular
disorders, but there are statistics showing that CTRP9 concentrations are decreased in patients with metabolic syndrome [20], but surprisingly elevated in obesity [21].
Although still under debate, some researches indicated that
CTRP3 also share a similar pattern. CTRP3 might increase
in obese subjects but decrease in T2DM patients [22–24].

In the present study, we observed that low CTRP3 or
CTRP9 levels are associated with a higher likelihood of
death and morbidity. Taken together with our data in previous basic research, CTRP3/CTRP9 may be a potential
therapeutic and diagnostic target.
CTRP3 and CTRP9 share a similar modular organization
with adiponectin [18], which is an insulin-sensitizing
adipokine with anti-inflammatory and anti-atherogenic
properties [25]. In the present study, we found CTRP3 and
CTRP9 concentrations to be decreased in HFrEF patients,
with the concentration negatively related to NYHA class.
However, evidence exists that APN levels are increased in
HFrEF patients [4]. In two previous cross-sectional studies,
researchers found in healthy subjects, CTRP3 (r = 0.194,
p < 0.001) and CTRP9 (r = 0.15, p < 0.03) are positively correlated with adiponectin, respectively. Therefore, we presume that although CTRP3, CTRP9 and APN have similar
biological activities and CTRP3/CTRP9 concentration are
positively related to the APN in healthy subjects, their relationship is not a causal relationship and the signaling pathways regulating the level of APN and CTRP3 and CTPR9
may be different.
Some research reported that the mRNA of CTRP3 in
fat tissue, and its serum levels are similar in both sex in
mice [26]. However, clinical trials showed that CTRP3
concentration was significantly higher in women than in
men [27]. Similarly, an animal study examining the level
of CTRP9 showed that female mice had higher levels
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than male mice [15]. Interestingly, contrary to the results
of the animal study, in a human study, CTRP9 concentration was not different according to sex [20]. We
found that in both healthy people or in patients with
HFrEF, the concentration of CTRP3 and CTRP9 were
not different in male and female. Our data support that
CTRP3 and CTRP9 levels are similar in both sexes.
Each member in the CTRP family has its own unique
biological activity [28]. However, to our knowledge, the relationships among CTPRs in the CTRP family have never
been reported. The present study is the first to demonstrate that CTRP3 and CTRP9 levels have a significantly
positive relationship in both healthy subjects and HFrEF
patients. Previous data suggest that CTRP3 reduces tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) secretion through suppression of nuclear factor κB signaling
pathway [29]. Moreover, TNFα can inhibit CTRP9 expression via oxidative stress-mediated inhibition of transcription factor PPARγ [30]. Thus, TNF-α might be the link in
regulating their levels in adipose tissue. In addition, we
have reported that supplementing either CTRP3 or CTRP9
can attenuate post-MI remodeling and augment post-MI
contractile function. In these experiments, whether replenishing one has an impact on the other during the MI
process to exert an anti-apoptotic or pro-angiogenic effect
remains unknown.
Several limitations exist in this study. First, this study enrolled a relatively small cohort of subjects from a single center. All were of Chinese ancestry. As such, generalizability to
other groups of patients must be evaluated going forward.
That said, our prospective study design in which we enrolled
consecutive patients mitigates some of these limitations.
Also, we did not measure changes in CTRP3/CTRP9 nor
clinical and biochemical characteristics during follow-up,
and hence, no causality of the interrelationship between
these parameters can be determined. Thirdly, because this is
the first study to examine CTRP3 and CTRP9 in relation to
prognosis in HFrEF, the present findings should be
confirmed in other studies.

Conclusion
We demonstrate that CTRP3 and CTRP9 are each decreased in patients with HFrEF, proportionate to disease
severity, and each is associated with increased morbidity
and mortality.
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